Saturday 17 October 2026 Export GSK’s income statement to Excel — free account

GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

49.55 0.53 +1.08%

Follow GSK

Alert me

Market cap: $98.2B
P/E: 15.4×
Fwd P/E: 12.4×
Dividend yield: 3.67%
F-score: 9/9
Altman Z: 2.12
Beneish M: −2.46
Dividend safety: 54/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.35%

Capital & Financial Ratios $m

Market Cap 98,210.00

Revenue 44,511.27

Net Income 6,938.53

Free Cash Flow 7,647.98

Net Debt 20,185.19

Current Ratio 0.82

Debt/Equity 1.06

P/E ratio 15.44

Fwd P/E 12.40

P/S ratio 2.23

P/B ratio 4.31

Past 5Y EPS Growth 0.04%

This Y EPS Growth 0.97%

Next Y EPS Growth 6.23%

Next Y revenue growth 3.60%

Next 5Y EPS Growth 4.14%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 54.52%

10-year low 10-year high

P/S against its own 10 years 79.84%

10-year low 10-year high

P/B against its own 10 years 34.39%

10-year low 10-year high

EV/Sales against its own 10 years 69.96%

10-year low 10-year high

EV/FCF against its own 10 years 61.31%

10-year low 10-year high

Dividends

Payout Ratio 0.57

Annual Dividend Rate 1.82

Annual Dividend Yield 3.67%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.91	0.48 0.46 0.45
2025	0.90	0.41 0.43 0.43 0.43
2024	1.56	0.40 0.38 0.39 0.38
2023	1.40	0.34 0.36 0.34 0.36
2022	1.89	0.75 0.43 0.37 0.33
2021	2.75	0.80 0.66 0.65 0.65
2020	2.56	0.71 0.59 0.62 0.65
2019	2.55	0.75 0.59 0.58 0.62
2018	2.67	0.81 0.63 0.62 0.60
2017	2.60	0.71 0.61 0.63 0.64
2016	1.79	0.71 0.63 0.58 0.58

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6,608	5,112	4,651	4,292
Receivables	9,650	9,361	10,232	10,836
Inventory	6,839	7,244	7,812	8,431
Other	—	—	—	—
	23,191	21,720	23,090	23,566

	2023	2024	2025	Q'26
Payables	19,708	19,597	20,283	19,248
ST’ Debt	3,499	3,002	3,972	5,759
Other	2,377	4,230	3,297	3,190
	26,206	27,727	28,208	28,901

Compound Annual Growth %

	10y	5y	3y
Sales	1.65%	(0.32%)	5.90%
Cash Flow	10.02%	(1.19%)	3.69%
Earnings	(5.21%)	0.42%	(25.86%)
Book Value	4.48%	(4.66%)	19.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10,280	11,286	—	—	—
’25	9,466	10,666	11,521	11,425	43,078
’24	9,337	9,950	10,420	10,388	40,095
’23	8,444	8,988	10,313	9,980	37,725
’22	13,123	8,699	9,221	5,228	36,271
’21	10,229	11,311	12,516	12,853	46,910
’20	11,644	9,461	11,169	11,509	43,783

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,537	3,604	—	—	—
’25	1,442	2,887	3,035	2,844	10,208
’24	1,215	1,399	2,881	2,880	8,375
’23	64	1,638	2,819	3,897	8,419
’22	3,411	1,833	1,231	2,681	9,157
’21	456	1,812	3,502	5,164	10,935
’20	1,236	3,386	1,302	4,914	10,838

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,060	3,127	—	—	—
’25	975	2,020	1,893	1,568	6,455
’24	536	848	1,877	1,553	4,815
’23	(565)	963	2,189	2,965	5,553
’22	2,625	1,354	886	1,923	6,787
’21	472	1,058	1,918	4,715	8,163
’20	948	3,553	491	4,671	9,662

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.15	0.29	—	—	—
’25	1.00	0.94	1.34	0.42	3.72
’24	0.65	0.72	(0.04)	0.26	1.59
’23	0.90	1.00	0.90	0.21	2.98
’22	1.20	0.52	5.94	0.92	9.19
’21	0.74	0.96	0.80	0.50	3.01
’20	1.00	1.41	0.81	0.45	3.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	37.20	34.52	34.89	37.60	31.43	33.53	28.47	33.20	32.83	31.72	Analyst estimates 2026–2028 Powerpack
	High	45.58	44.54	42.36	47.57	48.25	44.56	46.97	38.32	45.93	49.44
People
People	Employees	99,827	99,349	95,490	99,437	94,066	90,096	69,400	70,200	68,629	66,841
	Revenue/emp, $m	0.38	0.39	0.43	0.43	0.47	0.52	0.52	0.54	0.58	0.64
Income, $m
Income, $m	Revenue	37,798	38,904	41,140	43,100	43,783	46,910	36,271	37,725	40,095	43,078
	Gross margin, %	66.69	65.74	66.77	64.85	65.68	65.99	67.42	71.76	71.16	72.40
	EBT	2,628	4,543	6,407	7,944	8,947	7,483	6,961	7,543	4,443	9,760
	EBT margin, %	6.95	11.68	15.57	18.43	20.43	15.95	19.19	19.99	11.08	22.66
	Net income	1,439	2,795	5,401	6,727	8,202	7,008	6,087	6,603	3,771	8,293
	Depreciation	2,404	2,477	2,477	2,980	3,019	2,868	2,656	2,854	3,260	3,051
Per share, $
Per share, $	Revenue	19.44	19.91	20.93	21.78	22.00	23.44	18.02	18.62	19.67	21.27
	Earnings	0.64	1.01	2.46	3.00	3.71	3.01	9.19	3.02	1.61	3.72
	Cash flow	4.53	4.56	5.72	5.18	5.45	5.46	4.55	4.16	4.11	5.04
	Capex	(1.37)	(1.24)	(0.93)	(1.07)	(0.59)	(1.39)	(1.18)	(1.41)	(1.75)	(1.85)
	Free cash flow	3.16	3.33	4.79	4.10	4.85	4.08	3.37	2.74	2.36	3.19
	Book value	3.46	2.30	2.49	11.85	13.42	14.66	6.20	7.86	8.20	10.39
	Shares, m	1,944	1,954	1,966	1,979	1,990	2,001	2,013	2,026	2,039	2,026
Valuation, ×
Valuation, ×	P/E	64.73	37.40	15.68	15.80	9.98	14.64	4.07	12.42	21.14	13.22
	P/S	2.01	1.86	1.83	2.16	1.67	1.88	1.96	2.01	1.72	2.31
	P/B	11.24	16.05	15.32	3.97	2.74	3.01	5.69	4.77	4.12	4.72
	EV/Sales	2.50	2.29	2.54	2.91	2.28	2.46	2.40	2.43	2.13	2.74
	EV/FCF	15.34	13.70	11.09	15.44	10.32	14.12	12.82	16.53	17.76	18.29
Cash, $m
Cash, $m	Operating cash flow	8,805	8,916	11,240	10,241	10,838	10,935	9,157	8,419	8,375	10,208
	Capex	(2,671)	(2,414)	(1,831)	(2,125)	(1,176)	(2,772)	(2,370)	(2,866)	(3,560)	(3,753)
	Free cash flow	6,134	6,502	9,409	8,116	9,662	8,163	6,787	5,553	4,815	6,455
Balance, $m
Balance, $m	Working capital	(3,104)	(13,741)	(7,427)	(5,821)	(2,441)	(6,870)	(2,525)	(3,015)	(6,006)	(5,118)
	Total debt	25,466	22,024	34,790	38,956	34,861	33,240	25,959	22,413	21,706	23,367
	Net debt	18,497	16,896	29,256	32,307	26,486	27,021	15,981	15,805	16,595	18,716
	Shareholders’ equity	6,726	4,497	4,901	23,440	26,717	29,347	12,488	15,916	16,723	21,041
Returns, %
Returns, %	ROA	1.53	2.59	6.44	6.62	7.20	5.69	20.20	8.30	4.41	9.63
	ROIC	8.72	15.39	13.39	9.97	11.74	9.45	17.47	16.53	9.64	16.44
	ROE	12.18	35.19	102.91	41.86	29.43	21.51	88.44	43.16	20.16	39.92

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVS Novartis AG	$275.3B	22.6×	20.6×	+0.78% (above 0%: growing)	−17.39% (below 0%: shrinking)	−15.53% (below 0%: shrinking)	75.19%	31.77%	Compare
AZN AstraZeneca PLC	$258.5B	24.5×	23.4×	+6.41% (above 0%: growing)	+1.90% (above 0%: growing)	−107.45% (below 0%: shrinking)	83.60%	20.57%	Compare
AMGN Amgen Inc.	$234.7B	26.7×	22.7×	+9.53% (above 0%: growing)	+65.41% (above 0%: growing)	+82.57% (above 0%: growing)	72.04%	34.95%	Compare
GILD Gilead Sciences, Inc.	$195.1B	— (loss-making)	— (loss-making)	+10.18% (above 0%: growing)	n/m	+376.81% (above 0%: growing)	79.76%	(133.21%)	Compare
PFE Pfizer Inc.	$167.8B	38.9×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$131.2B	9.5×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$123.7B	13.2×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
GSK GSK PLC Sponsored ADR	$98.2B	15.4×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%
SNY Sanofi	$96.0B	21.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
Median of peers	$181.5B	22.6×	20.6×	+6.08%	−7.74%	+29.21%	75.33%	26.03%

All 21 Drug Manufacturers General stocks →

GSK PLC Sponsored ADR (GSK) key facts

Strength: GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
Strength: Net income was $8.3 billion, or $3.72 per share (basic), a net margin of 17.5%.
GSK PLC Sponsored ADR (GSK) is a Drug Manufacturers General company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, GSK traded at $49.55, a market capitalization of $98.2 billion.
At that price the stock trades at 15.4× trailing-twelve-month earnings and 2.2× sales; its P/E is higher than 55% of its own readings over the past ten years.
GSK PLC Sponsored ADR pays an annual dividend of $1.82 per share, a yield of 3.67%, with a payout ratio of 56.8%.
Return on equity was 39.9% and debt-to-equity 1.06.
Its Piotroski F-score is 9 out of 9 and its Altman Z-score is 2.12 (grey zone) for fiscal 2025.